Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.77 |
| ▸ | BRD9 | Q9H8M2 | 10/20 | 0.77 |
| ▸ | BRD2 | P25440 | 3/20 | 0.56 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21224468 | 0.90 | BRD4 (0.78) | BRD4BRD9BRD2BRD7CD274 | |
| SCHEMBL19869712 | 0.87 | BRD4 (1.00) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19857621 | 0.85 | BRD4 (1.00) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19869806 | 0.85 | BRD4 (0.78) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19857670 | 0.81 | BRD4 (0.67) | BRD4BRD9BRD2BRD7CD274 | |
| SCHEMBL19869729 | 0.80 | BRD4 (0.73) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19869715 | 0.78 | BRD4 (0.70) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL21224422 | 0.77 | BRD9 (0.61) | BRD4BRD9BRD7 | |
| SCHEMBL25844122 | 0.76 | BRD4 (0.67) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19857613 | 0.75 | BRD4 (0.62) | BRD4BRD9BRD2BRD7CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12351579-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11414416-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3917517-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-112236172-A | Methods and compounds for treating disorders | 福宏治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD2 79/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD2 79/4885 |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD2 79/4885 |
| US-11414416-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD2 79/4885 |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | BRD4 57/4885BRD9 330/4885BRD2 80/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | BRD4 57/4885BRD9 330/4885BRD2 80/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | BRD4 127/4885BRD9 1/4885BRD2 8/4885 |
| US-12351579-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD2 79/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.